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Abstract 
Objective: To assess the efficacy and safety of etanercept in severely active rheumatoid arthritis (RA) in a 
sample of Iraqi patients. 
Patients and methods: An open labeled single group prospective observational study was conducted over 15 
months on 190 Iraqi patients with RA diagnosed according to 1987 American College of Rheumatology criteria. 
All the included patients were given etanercept at a dose of 50 mg by subcutaneous injection on weekly bases. 
Disease activity score at 28 joints (DAS28) and functional class of RA were measured at baseline and after 
6months. 
Results: There was significant improvement in disease activity (DAS28) (p<0.001) with percent of change (-
29.26%) and functional disability (P=0.001) with etanercept use over a period of 6 months. Elevated liver 
transaminase were 3.68%, leucopenia 3.15%, headache 2.11%, itching 2.11%,  serious chest infection 1.57%, leg 
abscess 0.52%,  injection site reactions 1.05%, breast cancer  0.52, and  drug induced psoriasis 0.52%. 
Conclusion: Etanercept was effective and relatively safe in treatment of RA patients among Iraqi patients. 
Keywords: Etanercept, Rheumatoid arthritis, Diseases activity score 28 (DAS28).  
 
1. Introduction 
Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease that dramatically impairs quality of life 
[1]. Affected individuals experience significant morbidity, disability, and excess cardiovascular mortality [2]. 
The advent of targeted therapies, mainly against tumor necrosis factor alpha (TNF-α) have substantially changed 
the management and hence the prognosis of RA. Etanercept (ETN) was the first biologic response modifier to be 
approved by the US Food and Drug Administration (FDA) for use in RA [3]. Many clinical trials have reported 
that etanercept was safe and efficacious in active RA [4-9]. 
In Iraq, literature review revealed efficacy and safety of etanercept in ankylosing spondylitis patients, however 
there was no reports on its use in RA patients [10].  This study aimed to assess efficacy and safety of etanercept 
in a sample of Iraqi patients with severely active RA.  
 
2. Patients and Methods 
2.1 Study design 
This is an open labeled single group prospective study that was conducted over 15 months period on Iraqi 
patients with RA who were seen consecutively in the Rheumatology Clinic in Baghdad Teaching Hospital from 
May 2012 to July2013. All the included patients were given etanercept at a dose of 50 mg by subcutaneous 
injection on weekly bases from the start of the study to its end and patients were checked for efficacy and safety 
of the drug after 6 months. 
 The study was approved by the ethical committee of Medical Faculty in Baghdad Teaching Hospital 
and all patients gave their written informed consent prior to enrollment in the study 
 
2.2 Sample selection  
Patients were included in the study if they met the 1987 American College of Rheumatology criteria for the 
classification of RA, or had history of methotrexate intake for at least 3 months, patients with  DAS28 should be 
equal to or greater than 5.1 (severe disease activity). 
Patients were excluded from the study if they were less than 18 years old, or were taking other forms of disease 
modifying antirheumatic drugs (DMARDS), or had a previous history of biologic agents intake or had other 
connective tissue diseases overlapping with RA. 
 
2.3 Data collection and measurements 
For each patient, a baseline data were collected during the first visit and after six months. The collected data 
Journal of Natural Sciences Research                                                                                                                                                www.iiste.org 
ISSN 2224-3186 (Paper)   ISSN 2225-0921 (Online) 
Vol.5, No.2, 2015 
 
121 
included: patients’ age, sex, phone number, smoking status, disease duration,  and previous and current RA 
medications (DMARDs, corticosteroids and biologics). Assessment of disease activity was done by using 
DAS28 [11] and the functional status of the RA according to  the American College of Rheumatology 1991 
revised criteria for the classification of global functional status in rheumatoid arthritis [12]. 
  Laboratory data which include  rheumatoid factor (RF)  and hemoglobin (Hb) level, white blood cell 
(WBC) count, aspartate aminotransferase(AST), alanine aminotransferase (ALT),  blood urea and serum 
creatinine levels. (Performed during the first visit (baseline) and every subsequent visit).The side effects are 
checked and recorded for every patient in each visit.  
 
2.4 Statistical analysis 
A statistical software SPSS version 18 was used for analysis. A target sample size of 183 patients was calculated 
to provide approximately 90% statistical power with medium effect size of 30% and α error probability of 0.05 
as a significant level. Descriptive statistics were presented as mean, standard deviation, frequencies and 
percentages. Paired t test was used to compare the change of mean DAS28 at baseline and after six months while 
Chi square test (X2) was used to compare the change in functional class. p < 0.05 was considered as significant. 
 
3. Results 
Of a total 272 patients with RA, 195 patients met the inclusion criteria and 5 of those were lost during follow up 
leaving a total of 190 patients who successfully completed the study.  The mean age of patients was (47.43 ± 
11.9) years with a range of (20 - 95) years. The age was distributed into two categories; 52 patients (27.4%) were 
aged ≤ 40 years and 138 patients (72.6%) were aged > 40 years. Females were 158 (83.2%) and males were 32 
(16.8%). Patients with disease duration < 10 years were 111(58.4%) and those with disease duration ≥ 10 years 
were 79(41.6%). Smokers were 18 patients (9.5%), RF was positive in 119 patients (62.6%), and 162 patients 
(85.3%) were taking MTX as in Table 1. 
Etanercept significantly reduced DAS28 after 6months (Mean difference -1.75 ± 0.117, percent of 
change (-29.26 %), p<0.001) as in figure1. Also there was significant improvement in functional class with 
advancing treatment time. At baseline, 23 patients (12.1%) were functional class I, 70 patients (36.8%) were 
class II, 69 patients (36.3%) were class III and 28 patients (14.7%) were class IV. After sixth month of follow up 
the figures were changed to 106 patients (55.8%) in class I and only 9 patients (4.7 %) in class IV which is 
significant ( P = 0.001 ) as in Figure 2. 
The most common adverse effects reported in this study were elevation in liver transaminases (3.68%) 
then leucopenia (3.15%), and other side effects were shown in Table 2. 
 
 
           Table 1. Baseline characteristics of rheumatoid arthritis patients (N=190) 
 Variable N % 
Age (years) 
 
≤ 40 52 27.4 
> 40 138 72.6 
Sex 
Male 32 16.8 
Female 158 83.2 
Smoking 
Smoker 18 9.5 
 Non-smoker 172 90.5 
Disease duration 
 (years) 
< 10  111 58.4 
≥ 10  79 41.6 
Rheumatoid Factor 
Positive 119 62.6 
Negative 71 37.4 
Methotrexate 
Use 162 85.3 
Not uses 28 14.7 
               N, number; %, percentage 
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Figure 1. Disease activity index at 28 joints (DAS28) in severely active rheumatoid 
arthritis (N=190) at baseline and after 6months of etanercept therapy; N, number; 
SD; standard deviation, P significant <0.05 
 
 
       Figure 2. Functional class of rheumatoid arthritis patients at baseline and after 6 months of  etanercept 
treatment.    
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Table 2:  Frequency of adverse effects of etanercept treatment among 190 patients with rheumatoid arthritis in 
this study 
Adverse effects N     % 
Elevated Liver transaminases 7 3.68 
leucopoenia (<3000) 6 3.15 
Headache 4 2.11 
Itching 4 2.11 
 
Serious chest infection                         
            
Leg abscess 
 
3 
 
1.57 
 
1 
 
0.52 
 
Injection site reactions 
 
2 
 
1.05 
 
Breast cancer 
 
1 
 
0.52 
 
Drug induced psoriasis 
 
1 
 
0.52 
                N, number; %, percentage 
 
4. Discussion 
This  study assessed  efficacy and safety of etanercept in severely active  RA patients in Iraq. It showed clinically 
important and statistically significant reduction in disease activity (DAS28) (p<0.001, percent of change (-
29.26%) and significant with relevant improvement in the functional   disability   (p = 0.001) with etanercept use 
over a period of 6 months. In addition, etanercept was relatively safe with little adverse effects ranged from 
transient elevation of  liver transaminases (3.68%) and leucopenia (3.15%) which restored back to normal after 
withdrawing of etanercept for an average of  2 weeks duration to non-serious infections(chest infection (1.5%) 
and leg abscess(0.5%), injection site reaction(1.05%) and drug induced psoriasis(1.05%). 
Similar findings were reported by other studies. Weinblatt  et al [13]  evaluated safety and efficacy of 
etanercept beyond 10 years of therapy in North American patients with early and longstanding rheumatoid 
arthritis in open-label extension studies following initial double-blind trials of etanercept  and found that 
etanercept was well tolerated and effective as a long-term, continuous therapy for the treatment of RA, with a 
favorable risk/benefit ratio. 
    Another study from Japan, one of the largest observational trials conducted thus far in RA patients treated 
with biologics, evaluated the safety and effectiveness of etanercept in a 6-month postmarketing surveillance 
study covering all Japanese patients with rheumatoid arthritis (RA) who received etanercept during a 2-year 
period. Data for 13,894 patients (1334 sites) enrolled between March 2005 and April 2007 were collected and it 
showed that etanercept was effective and safe in Japanese patients [14]. 
In addition, Koike et al reported that Combination therapies with etanercept plus methotrexate or other 
DMARD were reasonably well tolerated, and a combined etanercept with methotrexate at higher doses was more 
effective than etanercept monotherapy in Japanese patients with RA [15]. 
Recently, Machado et al [16] compared in an open label observational study the addition of etanercept 
versus a conventional DMARDs in subjects with active RA despite methotrexate therapy in the Latin American 
region and concluded that adding etanercept to methotrexate demonstrated better efficacy than adding one other 
conventional DMARD to methotrexate. No new safety issues were observed. A combined etanercept with 
methotrexate provided a favorable benefit-risk profile among RA patients from LA region. 
The interpretation of the response to etanercept treatment may be related to no immunogenicity or 
insignificant immunogenicity against etanercept treatment as compared to other TNF blockers [17]. 
Notably, in the current study one patient developed breast cancer, although we were not sure whether 
this was an accidental finding or not because similar complication have not been reported in other studies. 
The main limitations of this study are open label study and no control arm was included. This makes it 
difficult to distinguish outcomes relating to etanercept treatment from those caused by other factors (like: patient 
expectations, natural history of the disease, or concomitant treatments) but longer-term blinded studies with 
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control arm may solve these problems. However this is the first study evaluating the efficacy and safety of 
etanercept in combination with methotrexate in inadequate responders to methotrexate with a sufficient sample 
size among Iraqi patients. 
 
5. Conclusion 
Etanercept was effective and relatively safe drug in treatment of a sample of Iraqi patients with severely active 
RA. This may suggest that early initiation of etanercept treatment to control inflammation in patients with active 
RA thus warrants consideration. 
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